Gelati M, Corsini E, Dufour A, Zaffaroni M, Milanese C, La Mantia L, Massa G, Salmaggi A
Istituto Nazionale Neurologico C. Besta, Milano, Italy.
Autoimmunity. 2001;33(4):275-83. doi: 10.1080/08916934.2002.11873704.
To evaluate the effects of in vivo beta-IFN-1b treatment on transmigration of mononuclear cells, we monitored for one year in vitro mononuclear cells trafficking through HUVECs monolayers stratified over a collagen gel during beta-IFN-1b treatment of 7 RR MS patients. The number of transmigrated cells was analysed before treatment (T0) and after 3 (T3), 6 (T6) and 12 months (T12); at the same time, levels of serum MMP-9 were quantified. The number of transmigrated cells decreased during treatment compared to pre-treatment values: the lowest number of transmigrated cells was detected at T3, and, although transmigration was still lower at T12, there was a trend to a return to pre-treatment levels over time. The amount of MMP-9 also decreased during therapy, although we could not find an absolute correlation between transmigration and levels of MMP-9, nor between either parameter and the clinical course of patients.
为了评估体内β-干扰素-1b治疗对单核细胞迁移的影响，我们在7例复发缓解型多发性硬化症（RR MS）患者接受β-干扰素-1b治疗期间，对体外通过铺在胶原凝胶上的人脐静脉内皮细胞（HUVECs）单层的单核细胞转运情况进行了为期一年的监测。在治疗前（T0）以及治疗3个月（T3）、6个月（T6）和12个月（T12）后分析迁移细胞的数量；同时，对血清基质金属蛋白酶-9（MMP-9）水平进行定量。与治疗前的值相比，治疗期间迁移细胞的数量减少：在T3时检测到迁移细胞的数量最少，并且尽管在T12时迁移率仍然较低，但随着时间的推移有恢复到治疗前水平的趋势。治疗期间MMP-9的量也减少，尽管我们未发现迁移与MMP-9水平之间存在绝对相关性，也未发现任一参数与患者临床病程之间存在相关性。
